Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE: DNA · Real-Time Price · USD
8.00
+0.06 (0.76%)
At close: Jun 11, 2026, 4:00 PM EDT
8.10
+0.10 (1.25%)
After-hours: Jun 11, 2026, 4:57 PM EDT
Ginkgo Bioworks Holdings Revenue
Ginkgo Bioworks Holdings had revenue of $19.47M in the quarter ending March 31, 2026, a decrease of -49.06%. This brings the company's revenue in the last twelve months to $121.84M, down -35.57% year-over-year. In the year 2025, Ginkgo Bioworks Holdings had annual revenue of $170.16M, down -25.06%.
Revenue (ttm)
$121.84M
Revenue Growth
-35.57%
P/S Ratio
3.45
Revenue / Employee
$312,163
Employees
485
Market Cap
522.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 170.16M | -56.89M | -25.06% |
| Dec 31, 2024 | 227.04M | -24.41M | -9.71% |
| Dec 31, 2023 | 251.46M | -226.25M | -47.36% |
| Dec 31, 2022 | 477.71M | 163.87M | 52.21% |
| Dec 31, 2021 | 313.84M | 237.18M | 309.40% |
| Dec 31, 2020 | 76.66M | 22.47M | 41.48% |
| Dec 31, 2019 | 54.18M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 389.42M |
| Valneva SE | 180.25M |
| Gyre Therapeutics | 117.05M |
| XOMA Royalty | 48.56M |
| Prime Medicine | 4.03M |
| ProKidney | 889.00K |
| Altimmune | 36.00K |
DNA News
- 16 days ago - Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery - PRNewsWire
- 5 weeks ago - Ginkgo Bioworks reaffirms 2026 expected total cash burn of ($150M)-($125M) - TheFly
- 5 weeks ago - Ginkgo Bioworks Holdings Earnings Call Transcript: Q1 2026 - Transcripts
- 5 weeks ago - Ginkgo Bioworks Holdings Earnings release: Q1 2026 - Filings
- 5 weeks ago - Ginkgo Bioworks Holdings Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Ginkgo Bioworks Holdings Slides: Q1 2026 - Filings
- 5 weeks ago - Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab - PRNewsWire
- 6 weeks ago - Ginkgo Bioworks Announces Date of First Quarter 2026 Results Presentation - PRNewsWire